Harrow (HROW) Cash from Financing Activities (2011 - 2026)
Harrow's (HROW) quarterly Cash from Financing Activities came in at $48.9 million in Q1 2026, up 212560.87% year-on-year from N/an in Q1 2025, and up 1069.71% quarter-over-quarter from -$5.0 million in Q4 2025.
Harrow (HROW) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Harrow's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $48.9 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 212560.87% year-over-year to $48.9 million in Q1 2026; TTM through Mar 2026 was $36.2 million, a 23.18% increase from a year earlier, with the FY2025 full-year figure at -$12.7 million, down 144.6% from the prior year.
- Cash from Financing Activities grew to $48.9 million in Q1 2026 per HROW's latest filing, from -$5.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $64.2 million in Q3 2023 and bottomed at -$12.7 million in Q2 2025.
- The 5-year median for Cash from Financing Activities is $48000.0 (2024), against an average of $15.3 million.
- Across the five-year window, Cash from Financing Activities surged 2751500.0% in 2022 and sank 17452.05% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $55.0 million in 2022, then slumped by 100.03% to -$18000.0 in 2023, then soared by 166683.33% to $30.0 million in 2024, then plunged by 116.82% to -$5.0 million in 2025, then soared by 1069.71% to $48.9 million in 2026.
- Per Business Quant, the three latest HROW Cash from Financing Activities figures stand at $48.9 million (Q1 2026), -$5.0 million (Q4 2025), and $5.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 48.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.91 Mn |
| Mar 31, 2026 | 48.91 Mn |
| Dec 31, 2025 | -5.04 Mn |
| Dec 31, 2025 | -5.04 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | -12.67 Mn |
| Jun 30, 2025 | -12.67 Mn |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 29.99 Mn |
| Dec 31, 2024 | 29.99 Mn |
| Sep 30, 2024 | -721,000.00 |
| Sep 30, 2024 | -721,000.00 |
| Jun 30, 2024 | 73,000.00 |
| Jun 30, 2024 | 73,000.00 |
| Mar 31, 2024 | -809,000.00 |
| Mar 31, 2024 | -809,000.00 |
| Dec 31, 2023 | -18,000.00 |
| Dec 31, 2023 | -18,000.00 |